The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.
 
Scott Norberg
Travel, Accommodations, Expenses - Kite/Gilead
Other Relationship - Kite/Gilead
 
Nisha Nagarsheth
Travel, Accommodations, Expenses - Kite/Gilead
Other Relationship - Kite/Gilead
 
Andrew Sinkoe
Other Relationship - Kite/Gilead
 
Sabina Adhikary
Employment - Kite, a Gilead company
Stock and Other Ownership Interests - Kite/Gilead
 
Thomas Meyer
No Relationships to Disclose
 
Justin Lack
No Relationships to Disclose
 
Jennifer Ann Kanakry
No Relationships to Disclose
 
Mohammadhadi Bagheri
No Relationships to Disclose
 
Colleen Schweitzer
Employment - Kite/Gilead
Stock and Other Ownership Interests - Kite/Gilead
Travel, Accommodations, Expenses - Kite/Gilead
 
Stephanie H. Astrow
Employment - Kite/Gilead
Stock and Other Ownership Interests - Kite/Gilead
Travel, Accommodations, Expenses - Kite/Gilead
 
Adrian Bot
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
David Stroncek
No Relationships to Disclose
 
Nikolaos Gkitsas
No Relationships to Disclose
 
Steven Highfill
No Relationships to Disclose
 
Christian S. Hinrichs
Employment - Ipsen (I); Ipsen (I)
Research Funding - Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - Patent related to combined checkpoint blockade and TGF beta inhibition in HPV+ cancers; Patents in the field of cell therapy that are held by the NIH.; Royalties from patents that are held by the NIH.